Fischer Laurent's Form 4 filing
AtaiBeckley Inc. (ATAI) · filed Sep 11, 2026
- Accession no.
- 0001140361-26-036384
- Filed
- Sep 11, 2026, 5:44 PM ET
- Trade date
- Sep 11, 2026
- Filing delay
- Same day
- Rule 10b5-1 plan
- Not checked
This filing lists 3 derivative transactions. It was filed on the trade date.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Fischer LaurentCIK 0001379344 | Director |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
This filing has no transactions of this kind.
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Sep 11, 2026 | Common Stock | DReturned to the companyDisposed | −206,000 | –F2 | – | 0 | Direct | |
| Sep 11, 2026 | Common Stock | DReturned to the companyDisposed | −103,000 | –F2 | – | 0 | Direct | |
| Sep 11, 2026 | Common Stock | DReturned to the companyDisposed | −121,968 | –F2 | – | 0 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F2
At the effective time of the Merger (the "Effective Time"), each outstanding stock option of the Company, subject to certain exceptions, was automatically cancelled and converted into the right to receive (A) an amount in cash (without interest and less applicable tax withholdings) equal to the product of (1) the total number of shares of the Company's common stock subject to such stock option immediately prior to the Effective Time multiplied by (2) the excess of $6.75 over the applicable exercise price per share under such stock option and (B) one contingent value right per share (each, a "CVR" and collectively, the "CVRs"), representing the right to receive up to an aggregate of $2.50 in cash per CVR upon achievement, if any, of specified clinical and regulatory milestones, less any applicable tax withholding, for each share subject to such stock option immediately prior to the Effective Time (without regard to vesting).
Referenced by the price of 3 transactions in Table II.